The regulatory and funding frameworks underpinning ImpediMed's US commercialisation pathway continue to strengthen, Ord Minnett notes, and new management is pulling the right levers to position the business for material growth from FY25 onwards.

With the positive impacts from realigning the sales team initiatives and critical mass reimbursement in their infancy, March Q US SOZO sales, while disappointing, were not unexpected.

Ord Minnett expects an acceleration in US installed base growth in the first half FY25, with payor updates and potential multi-site Integrated Delivery Network contracts looming as nearer term catalysts.

Speculative Buy and 16c target retained.

Sector: Health Care Equipment & Services.

Target price is $0.16.Current Price is $0.08. Difference: $0.08 - (brackets indicate current price is over target). If IPD meets the Ord Minnett target it will return approximately 50% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2024 Acquisdata Pty Ltd., source FN Arena